Solventum Corp

Solventum reported Q2 2026 net sales of $2.21 billion, a 2.2% increase year-over-year, with net income rising slightly to $92 million. However, for the first half of 2026, net income decreased significantly by 53.7% to $105 million, and operating income fell by 28.6% to $262 million. The company repurchased $355 million in shares and updated on its Acera Surgical acquisition, where the contingent payment fair value increased to $92 million due to sales performance.

Solventum reported strong second-quarter 2026 financial results, with reported sales increasing 2.2% to $2.2 billion and organic sales up 9.5%. Adjusted diluted earnings per share surged 50.9% to $2.55, and free cash flow reached $144 million. The company also announced its intent to separate its Health Information Systems business segment to enhance focus and shareholder value. Consequently, Solventum raised its full-year 2026 guidance for organic sales growth, adjusted EPS, and free cash flow.

Solventum announced its intention to separate its Health Information Systems business as part of an ongoing portfolio optimization strategy. This move aims to strengthen Solventum's focus as a dedicated MedTech company and unlock shareholder value. The Health Information Systems business, which generated $1.4 billion in annual sales in 2025, operates in a $10 billion market and will be positioned for accelerated growth as a separate entity. Solventum is evaluating various separation pathways and targets completion within 12 to 18 months.

Solventum Corporation has appointed Neil Zieselman as its new Senior Vice President, Controller, and Chief Accounting Officer, effective August 10, 2026. Mr. Zieselman will replace Mary Wilcox, who is retiring, and will report to CFO Wayde McMillan. His compensation package includes an annual bonus target of 50% of base salary, a $500,000 long-term incentive award, a $130,000 cash sign-on bonus, and $600,000 in restricted stock units.

Solventum Corp. has agreed to pay $120,000 in attorneys' fees and expenses to settle a class action lawsuit filed by a stockholder challenging certain by-law provisions related to advance notice and stockholder nominations. While the company denies all allegations, it opted to resolve the matter to avoid further litigation costs. The lawsuit was dismissed as moot after the company amended its by-laws, and the Delaware Court has entered an order closing the case.

Solventum Corporation adopted a new Executive Severance Plan, effective June 1, 2026, which supersedes the prior plan from April 1, 2024. The plan provides severance payments and benefits, including 9 to 24 months of base salary, continued incentive compensation, and medical/dental coverage, for eligible employees in cases of involuntary termination or voluntary termination for good reason. Notable changes include 12 months of base salary for direct reports of the CEO (with some executives retaining 18 months for two years) and a lump-sum COBRA payment for the CEO and direct reports.

Solventum reported a significant decline in its first-quarter 2026 financial results, with net income falling to $13 million from $137 million year-over-year, and diluted EPS dropping to $0.07 from $0.78. Total net sales decreased by 3.04% to $2,007 million. The company also reported negative cash flow from operating activities of $189 million and repurchased $67 million in common stock.

Solventum reported first-quarter 2026 financial results, with reported sales decreasing 3.0% to $2.0 billion, but organic sales increasing 2.1%. The company achieved adjusted diluted EPS of $1.48, a 10.6% increase year-over-year, and affirmed its full-year 2026 organic sales growth and free cash flow guidance, estimating adjusted EPS toward the high end of its existing range. The company also highlighted the opening of a new R&D center and a manufacturing expansion.